Patents by Inventor Seong Ran LEE

Seong Ran LEE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11786450
    Abstract: A fusion protein includes heat shock protein 10 and brazzein protein. The fusion protein has an enhanced anti-oxidation activity and skin cell proliferation effect. It can be used as a cosmetic composition for ameliorating skin wrinkles. The cosmetic composition including the fusion protein can be advantageously used in future as a material of a functional cosmetic product.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: October 17, 2023
    Assignees: NEXGEN BIOTECHNOLOGIES, INC.
    Inventors: Sun Kyo Lee, Seong Ran Lee, Han Bong Ryu, Tae Hyun Kim, Tae Won Choi
  • Publication number: 20230312545
    Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additionally, the present invention provides novel intermediates useful for said process and processes for preparing the same.
    Type: Application
    Filed: June 2, 2023
    Publication date: October 5, 2023
    Inventors: Sang-Ho Oh, Ja-Heouk Khoo, Jong-Chul Lim, Seong-Ran Lee, Hyun Ju, Woo-Seob Shin, Dae-Gyu Park, Su-Min Park, Yoon-Ah Hwang
  • Patent number: 11708362
    Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additional, the present invention provides novel intermediates useful for said process and processes for preparing the same.
    Type: Grant
    Filed: March 25, 2022
    Date of Patent: July 25, 2023
    Assignee: Yuhan Corporation
    Inventors: Sang-Ho Oh, Ja-Heouk Khoo, Jong-Chul Lim, Seong-Ran Lee, Hyun Ju, Woo-Seob Shin, Dae-Gyu Park, Su-Min Park, Yoon-Ah Hwang
  • Publication number: 20230190618
    Abstract: A fusion protein includes heat shock protein 10 and brazzein protein. The fusion protein has an enhanced anti-oxidation activity and skin cell proliferation effect. It can be used as a cosmetic composition for ameliorating skin wrinkles. The cosmetic composition including the fusion protein can be advantageously used in future as a material of a functional cosmetic product.
    Type: Application
    Filed: June 1, 2017
    Publication date: June 22, 2023
    Inventors: Sun Kyo LEE, Seong Ran LEE, Han Bong RYU, Tae Hyun KIM, Tae Won CHOI
  • Publication number: 20230021395
    Abstract: The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.
    Type: Application
    Filed: March 17, 2022
    Publication date: January 26, 2023
    Inventors: Sang Ho OH, Jong Gyun KIM, Se-Woong OH, Tae Dong HAN, Soo Yong CHUNG, Seong Ran LEE, Kyeong Bae KIM, Young Sung LEE, Woo Seob SHIN, Hyun JU, Jeong Ki KANG, Su Min PARK, Dong Kyun KIM
  • Patent number: 11453656
    Abstract: The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yppyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: September 27, 2022
    Assignee: Yuhan Corporation
    Inventors: Sang Ho Oh, Jong Gyun Kim, Se-Woong Oh, Tae Dong Han, Soo Yong Chung, Seong Ran Lee, Kyeong Bae Kim, Young Sung Lee, Woo Seob Shin, Hyun Ju, Jeong Ki Kang, Su Min Park, Dong Kyun Kim
  • Publication number: 20220281861
    Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additional, the present invention provides novel intermediates useful for said process and processes for preparing the same.
    Type: Application
    Filed: March 25, 2022
    Publication date: September 8, 2022
    Inventors: Sang-Ho Oh, Ja-Heouk Khoo, Jong-Chul Lim, Seong-Ran Lee, Hyun Ju, Woo-Seob Shin, Dae-Gyu Park, Su-Min Park, Yoon-Ah Hwang
  • Publication number: 20220192958
    Abstract: A fusion protein according to an embodiment of the present disclosure includes a growth differentiation factor 11 and a heat shock protein 10 with an enhanced skin cell proliferation effect. An anti-wrinkle cosmetic composition according to an embodiment of the present disclosure includes the fusion protein as an effective component, and the cosmetic composition can be advantageously used in future as a material of a functional cosmetic product.
    Type: Application
    Filed: August 1, 2017
    Publication date: June 23, 2022
    Inventors: Sun Kyo LEE, Seong Ran LEE, Han Bong RYU, Tae Hyun KIM
  • Publication number: 20220160609
    Abstract: A fusion protein according to an embodiment of the present disclosure includes a growth differentiation factor 11 and an epidermal growth factor with an enhanced anti-oxidation activity and an enhanced skin cell proliferation effect, A cosmetic composition according to an embodiment of the present disclosure includes the fusion protein as an effective component. The cosmetic composition can be advantageously used in future as a material of a functional cosmetic product.
    Type: Application
    Filed: June 1, 2017
    Publication date: May 26, 2022
    Inventors: Sun Kyo LEE, Seong Ran LEE, Han Bong RYU, Tae Hyun KIM
  • Patent number: 11286253
    Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additional, the present invention provides novel intermediates useful for said process and processes for preparing the same.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: March 29, 2022
    Assignee: Yuhan Corporation
    Inventors: Sang-Ho Oh, Ja-Heouk Khoo, Jong-Chul Lim, Seong-Ran Lee, Hyun Ju, Woo-Seob Shin, Dae-Gyu Park, Su-Min Park, Yoon-Ah Hwang
  • Patent number: 11166898
    Abstract: A human growth hormone fusion protein has enhanced thermal stability. The human growth hormone fusion protein has the amino acid sequence SEQ ID NO: 3 or SEQ ID NO: 4. A gene encoding the human growth hormone fusion protein has E. coli codon-optimized nucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 6. A recombinant vector includes the aforementioned gene. A host cell is transformed with the aforementioned recombinant vector. A method for producing in a host cell a human growth hormone fusion protein includes transforming a host cell with the aforementioned recombinant vector. The human growth hormone fusion protein may improve skin wrinkle and maintain skin elasticity. As the human growth hormone fusion protein has thermal stability and also has an effect of improving skin wrinkle and increasing the effect of maintaining skin elasticity, it can be advantageously used as a raw material of cosmetics.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: November 9, 2021
    Assignees: NEXGEN BIOTECHNOLOGIES, INC.
    Inventors: Sun Kyo Lee, Seong Ran Lee, Han Bong Ryu, Tae Won Choi, Tae Hyun Kim
  • Publication number: 20210269427
    Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additional, the present invention provides novel intermediates useful for said process and processes for preparing the same.
    Type: Application
    Filed: December 8, 2020
    Publication date: September 2, 2021
    Inventors: Sang-Ho Oh, Ja-Heouk Khoo, Jong-Chul Lim, Seong-Ran Lee, Hyun Ju, Woo-Seob Shin, Dae-Gyu Park, Su-Min Park, Yoon-Ah Hwang
  • Publication number: 20210139461
    Abstract: The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yppyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.
    Type: Application
    Filed: April 18, 2018
    Publication date: May 13, 2021
    Inventors: Sang Ho OH, Jong Gyun KIM, Se-Woong OH, Tae Dong HAN, Soo Yong CHUNG, Seong Ran LEE, Kyeong Bae KIM, Young Sung LEE, Woo Seob SHIN, Hyun JU, Jeong Ki KANG, Su Min PARK, Dong Kyun KIM
  • Publication number: 20210100729
    Abstract: A fusion protein of heat shock proteins has an increased anti-oxidant activity and skin cell proliferation effect. An anti-wrinkle composition which has the fusion protein as an effective component can be advantageously used as a material of a functional cosmetic product. The fusion protein may be composed of heat shock protein 10 and heat shock protein 20. The fusion protein may include the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.
    Type: Application
    Filed: August 1, 2017
    Publication date: April 8, 2021
    Applicants: NEXGEN BIOTECHNOLOGIES, INC.
    Inventors: Sun Kyo LEE, Seong Ran LEE, Han Bong RYU, Tae Hyun KIM, Tae Won CHOI
  • Patent number: 10889578
    Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. And also, the present invention provides novel intermediates useful for said process and processes for preparing the same.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: January 12, 2021
    Assignee: Yuhan Corporation
    Inventors: Sang-Ho Oh, Ja-Heouk Khoo, Jong-Chul Lim, Seong-Ran Lee, Hyun Ju, Woo-Seob Shin, Dae-Gyu Park, Su-Min Park, Yoon-Ah Hwang
  • Publication number: 20200405612
    Abstract: A human growth hormone fusion protein has enhanced thermal stability. The human growth hormone fusion protein has the amino acid sequence SEQ ID NO: 3 or SEQ ID NO: 4. A gene encoding the human growth hormone fusion protein has E. coli codon-optimized nucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 6. A recombinant vector includes the aforementioned gene. A host cell is transformed with the aforementioned recombinant vector. A method for producing in a host cell a human growth hormone fusion protein includes transforming a host cell with the aforementioned recombinant vector. The human growth hormone fusion protein may improve skin wrinkle and maintain skin elasticity. As the human growth hormone fusion protein has thermal stability and also has an effect of improving skin wrinkle and increasing the effect of maintaining skin elasticity, it can be advantageously used as a raw material of cosmetics.
    Type: Application
    Filed: January 9, 2017
    Publication date: December 31, 2020
    Inventors: Sun Kyo LEE, Seong Ran LEE, Han Bong RYU, Tae Won CHOI, Tae Hyun KIM
  • Patent number: 10815284
    Abstract: A fusion protein has the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. A composition having the fusion protein may improve skin wrinkle with increased anti-oxidant activity and skin cell proliferation effect. It can be advantageously used as a raw material of a functional cosmetic having an excellent skin regeneration effect like improvement of skin wrinkles and skin whitening.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: October 27, 2020
    Assignees: NEXGEN BIOTECHNOLOGIES, INC.
    Inventors: Sun Kyo Lee, Tae Hyun Kim, Seong Ran Lee, Han Bong Ryu, Tae Won Choi, Hyeong Il Kwon, Woo Yeon Roh
  • Publication number: 20200165236
    Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. And also, the present invention provides novel intermediates useful for said process and processes for preparing the same.
    Type: Application
    Filed: July 25, 2018
    Publication date: May 28, 2020
    Inventors: Sang-Ho OH, Ja-Heouk KHOO, Jong-Chul LIM, Seong-Ran LEE, Hyun JU, Woo-Seob SHIN, Dae-Gyu PARK, Su-Min PARK, Yoon-Ah HWANG
  • Patent number: 10441632
    Abstract: A method for treating wrinkle or aging on a skin of a subject includes applying to the skin a composition that includes a green fluorescent protein-human epidermal growth factor fusion protein as an effective component. Since the fusion protein has an excellent anti-oxidation activity and a high skin cell proliferation effect, it can be advantageously used as a raw material of functional cosmetics having excellent skin regeneration effect like improvement of skin wrinkles and skin whitening.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: October 15, 2019
    Assignees: NEXGEN BIOTECHNOLOGIES, INC.
    Inventors: Sun Kyo Lee, Seong Ran Lee, Han Bong Ryu, Tae Hyun Kim, Tae Won Choi, Hyeong Il Kwon
  • Publication number: 20190218266
    Abstract: A fusion protein has the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. A composition having the fusion protein may improve skin wrinkle with increased anti-oxidant activity and skin cell proliferation effect. It can be advantageously used as a raw material of a functional cosmetic having an excellent skin regeneration effect like improvement of skin wrinkles and skin whitening.
    Type: Application
    Filed: August 31, 2017
    Publication date: July 18, 2019
    Inventors: Sun Kyo LEE, Tae Hyun KIM, Seong Ran LEE, Han Bong RYU, Tae Won CHOI, Hyeong Il KWON, Woo Yeon ROH